Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 3/20 | 0.49 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TOP1 | P11387 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.38 |
| ▸ | CETP | P11597 | 2/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31338862 | 1.00 | GGPS1 (0.49) | GGPS1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL17817249 | 1.00 | GGPS1 (0.49) | GGPS1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL12258773 | 1.00 | GGPS1 (0.49) | GGPS1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL9813074 | 1.00 | GGPS1 (0.49) | GGPS1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL13169240 | 1.00 | GGPS1 (0.49) | GGPS1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL23016843 | 1.00 | GGPS1 (0.49) | GGPS1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL4754900 | 1.00 | GGPS1 (0.49) | GGPS1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL8640646 | 1.00 | GGPS1 (0.49) | GGPS1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL13169239 | 1.00 | GGPS1 (0.49) | GGPS1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL31201935 | 1.00 | GGPS1 (0.49) | GGPS1S1PR2S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120053661-A | Hydrophilic fatty acid complex for preventing, preventing or treating microbial infection, preparation and application thereof | 太阳雨林(北京)生物医药有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-120053660-A | Hydrophilic complex for preventing, preventing or treating microbial infection, preparation and application thereof | 太阳雨林(北京)生物医药有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-119855607-A | Carbon chain substance for regulating transmembrane transport and fluidity of cell membrane, preparation and application | 太阳雨林(北京)生物医药有限公司 | 2025-04-18 | — | — | CN | disclosed |
| EP-4520348-A1 | CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF | Sunforest (Beijing) Biopharma Ltd (CN) | 2025-03-12 | — | — | EP | disclosed |
| CN-119015434-A | Complex for preventing, preventing or treating microbial infection, preparation method and application thereof | 太阳雨林(北京)生物医药有限公司 | 2024-11-26 | — | — | CN | disclosed |
| US-11801231-B2 | Oral compositions and methods of use | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-10-31 | — | — | US | disclosed |
| EP-3727336-A1 | ORAL COMPOSITIONS AND METHODS OF USE | 3M Innovative Properties Company (US) | 2020-10-28 | — | — | EP | disclosed |
| EP-2180873-B1 | Therapeutic dental composition for use in the inhibition of biofilm formation in the oral cavity. | 3M INNOVATIVE PROPERTIES CO (US) | 2018-04-11 | — | — | EP | disclosed |
| US-8968709-B2 | Therapeutic dental composition and related methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-03-03 | — | — | US | disclosed |
| US-8647608-B2 | Therapeutic dental composition and related methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2180873-A1 | THERAPEUTIC DENTAL COMPOSITION AND RELATED METHODS | 3M Innovative Properties Company (US) | 2010-05-05 | — | — | EP | disclosed |
| US-20090305196-A1 | DENTAL COMPOSITIONS INCLUDING ORGANOGELATORS, PRODUCTS, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2009-12-10 | — | — | US | disclosed |
| US-20090305196-A1 | DENTAL COMPOSITIONS INCLUDING ORGANOGELATORS, PRODUCTS, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2009-12-10 | — | — | US | disclosed |
| US-20090305196-A1 | DENTAL COMPOSITIONS INCLUDING ORGANOGELATORS, PRODUCTS, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2009-12-10 | — | — | US | disclosed |
| EP-2073782-A2 | DENTAL COMPOSITIONS INCLUDING ORGANOGELATORS, PRODUCTS, AND METHODS | 3M Innovative Properties Company (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2009014907-A1 | THERAPEUTIC DENTAL COMPOSITION AND RELATED METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-01-29 | — | — | WO | disclosed |
| WO-2008033911-A2 | DENTAL COMPOSITIONS INCLUDING ORGANOGELATORS, PRODUCTS, AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-03-20 | — | — | WO | disclosed |
| US-6498236-B1 | HYBRIDOMA CELL CULTURE SUPERNATANTS, ANIMAL PLASMA OR SERA, OR COLOSTRUM. THE METHOD INCLUDES THE USE OF A MINIMUM OF SALTS, SUCH AS LYOTROPIC SALTS, IN THE BINDING PROCESS AND PREFERABLY ALSO THE USE OF SMALL AMOUNTS OF ORGANIC SOLVENTS IN THE | UPFRONT CHROMATOGRAPHY A/S (DK) | 2002-12-24 | — | — | US | disclosed |
| EP-0742280-A2 | Automatic dishwashing compositions comprising multiquarternary bleach activators | THE PROCTER & GAMBLE COMPANY (US) | 1996-11-13 | — | — | EP | disclosed |
| US-5520835-A | Automatic dishwashing compositions comprising multiquaternary bleach activators | THE PROCTER & GAMBLE COMPANY (US) | 1996-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090305196-A1 | DENTAL COMPOSITIONS INCLUDING ORGANOGELATORS, PRODUCTS, AND METHODS | DDOST, DNA2, KRTCAP2 | GGPS1 1117/4885S1PR2 4553/4885S1PR1 4670/4885 |
| US-11801231-B2 | Oral compositions and methods of use | HRH2, HRH3, TAS2R42 | GGPS1 3599/4885S1PR2 68/4885S1PR1 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.